An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.
Authors: Spencer Andrew , Grigg Andrew , Catalano John , Leahy Michael , Underhill Craig , Arthur Chris , DRozario James , Lowenthal Ray , Taylor Kerry 
Published: April 2020

Abstract
We have previously demonstrated significant anti-lymphoma activity using an outpatient-based salvage approach comprising vinorelbine and gemcitabine with an overall response (CR + PR) rate of 55%. We now report the results of a planned interim analysis of a similar outpatient approach for both non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL) but incorporating patient stratification and treatment escalation. Patients were stratified into Group 1 (G1 - good risk - first relapse following durable first remission - follicular NHL&gt;12 months, all other NHL sub-types and HL&gt;6 months); Group 2 (G2 - poor risk - primary refractory, second or subsequent relapse, or non-durable first remission); or Group 3 (G3 - post-transplant - relapse following any form of stem cell transplant therapy). Two chemotherapy regimens were evaluated. VGF (vinorelbine 25mg/sqm days 1 and 8, gemcitabine 1000mg/sqm days 1 and 8, pegfilgrastim 6mg SC day 9); F-GIV (same as VGF but with ifosfamide 3000mg/sqm day 1 with mesna uroepithelial protection). G1 and G3 commenced therapy with VGF and G2 with F-GIV. Following 2 cycles of therapy all patients were restaged. Any patients demonstrating disease progression were removed from trial. Responsive patients (&gt;50% reduction in all previous sites of disease and gallium and/or FDG-PET negativity where baseline positivity was demonstrated) received 2 further cycles of the same therapy, the remainder ‘escalated’ therapy with F-GIV (G1 and G3) or IVAC (G2) (inpatient treatment with ifosfamide, VP-16 and Ara-C). A planned total of 90 patients were accrued between December 2002 and December 2004. Here we report on the first 88 patients (G1 = 26, G2 = 50, G3 = 12) with a median age of 57 years (range, 17–78). Diagnoses at entry were HL, n = 16 (nodular sclerosing = 13, mixed cellularity = 3) and NHL, n = 72 (diffuse large cell = 41, follicular = 16, others = 15). So far G1 and G2 have received 79 and 138 cycles of VGF and F-GIV, respectively, with grades 3/4 neutropenia or thrombocytopenia occurring in 24% and 18% (VGF) and 62% and 49% (F-GIV) of patients, respectively. Significant non-haematological toxicities were uncommon. Febrile neutropenia, hospital admission, treatment delay or dose-reductions occurred with 4%, 19%, 4%, 1% and 17%, 34%, 9%, 9% of VGF and F-GIV cycles, respectively. The 12 post-transplant patients (G3) have received 28 and 8 cycles of VGF and F-GIV, respectively, with no unexpected toxicities. Based on published standardised response criteria overall response (CR + Cru + PR) on an intention-to-treat basis after 2 to 4 cycles of treatment is 54% (CR 29%) (77% and 42% for G1 and G2, respectively). Diffuse large cell NHL patients have demonstrated response rates of 67% and 17% for G1 and G2 patients, respectively. Based on this planned interim analysis we conclude that both VGF and F-GIV can be safely administered on an outpatient basis and show activity against advanced lymphoma.